AMN Healthcare Services (AMN)
(Real Time Quote from BATS)
$57.08 USD
+0.79 (1.40%)
Updated Jul 17, 2024 03:55 PM ET
After-Market: $57.03 -0.05 (-0.09%) 4:18 PM ET
5-Strong Sell of 5 5
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.08 USD
+0.79 (1.40%)
Updated Jul 17, 2024 03:55 PM ET
After-Market: $57.03 -0.05 (-0.09%) 4:18 PM ET
5-Strong Sell of 5 5
A Value C Growth B Momentum B VGM
Zacks News
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Strong adoption of the MITRIS RESILIA valve and increased demand for the HemoSphere monitoring platform will likely drive Edwards Lifesciences' (EW) Q4 revenues.
Here's Why Investors Should Retain Globus Medical (GMED) Stock
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.
4 Solid Net Profit Margin Stocks to Maximize Portfolio Returns
by Anirudha Bhagat
Here are four top-ranked stocks, SNEX, HHS, VRTV and AMN, with solid net profit margins that can contribute toward making a solid portfolio.
UnitedHealth (UNH) Beats on Q4 Earnings, Retains 2023 View
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results gain from sustained membership growth in its UnitedHealthcare business.
Charles River (CRL) to Advance DNA Programs With New Launch
by Zacks Equity Research
Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.
NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue
by Zacks Equity Research
NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.
Intuitive Surgical (ISRG) Reports Mixed Preliminary Q4 Revenues
by Zacks Equity Research
Intuitive Surgical's (ISRG) revenue growth in the fourth quarter is driven by increase in procedure volume, partially offset by resurgence of COVID-19 in China.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Inogen (INGN) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.
PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.
Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.
QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails
by Zacks Equity Research
The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.
Brookdale Senior Living (BKD) Q4 Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 14 straight months of year-over-year increases in weighted average occupancy level.
Syneos Health (SYNH) to Launch Serplulimab With New Pact
by Zacks Equity Research
Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $110.88, moving -1.55% from the previous trading session.
Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Here's Why Investors Should Buy Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit
by Zacks Equity Research
A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
DexCom (DXCM) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
by Zacks Equity Research
QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.